GlassScriptPhysician profile
Lynn Van Ummersen
NPI 1447211818
$7,770.46
in general payments reported to CMS, 2019-2025
68 companies · $2,227 in 2025
The $2,227 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $733 · 2020: $331 · 2021: $323 · 2022: $990 · 2023: $1,435 · 2024: $1,732 · 2025: $2,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,219 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,218.61 |
| Education | $174.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $968.42 | 2019-2025 | |
| Janssen Biotech, INC. | $578.85 | 2019-2025 | Rybrevant, Talvey, Erleada |
| Celgene Corporation | $384.29 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Abbvie INC. | $358.03 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $340.81 | 2020-2025 | Enhertu, Imfinzi, Calquence |
| Pfizer INC. | $337.69 | 2019-2025 | |
| Daiichi Sankyo INC. | $313.92 | 2019-2025 | Enhertu, Vanflyta, Injectafer |
| Merck Sharp & Dohme LLC | $299.34 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Gilead Sciences, INC. | $273.31 | 2023-2025 | Trodelvy |
| Lilly USA, LLC | $251.10 | 2019-2025 | Jaypirca, Retevmo, Verzenio |
| E.R. Squibb & Sons, L.L.C. | $248.61 | 2019-2025 | Opdivo |
| Eisai INC. | $234.64 | 2019-2025 | |
| Incyte Corporation | $208.36 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Genzyme Corporation | $204.73 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $201.13 | 2019-2023 | Imbruvica, Epkinly |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Van Ummersen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.